Bristol-Myers Squibb BMY Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.68B+147% | $1.09B-50.6% | $2.2B+67.2% | $1.31B-46.7% | $2.46B— | ||
| $594M-39.2% | $977M-3.4% | $1.01B0.0% | $1.01B-0.1% | $1.01B-46.2% | ||
| $146M+9.8% | $133M-4.3% | $139M+1.5% | $137M-4.9% | $144M+20.0% | ||
| $161M+141% | -$392M-9.2% | -$359M+17.8% | -$437M-296% | $223M+128% | ||
| -$14M— | —— | $90M— | —— | $169M— | ||
| $409M+554% | -$90M-156% | $160M— | —— | -$85M-116% | ||
| $1.64B+253% | -$1.07B— | —— | —— | $1.06B+246% | ||
| $187M+158% | -$324M-137% | $887M+243% | -$621M-1,250% | $54M— | ||
| -$1.69B— | —— | —— | $484M+3,327% | -$15M+89.5% | ||
| $1.1B-44.1% | $1.97B-68.7% | $6.31B+61.1% | $3.92B+100% | $1.95B-56.0% | ||
| $347M-6.2% | $370M+15.6% | $320M-11.4% | $361M+38.8% | $260M-31.2% | ||
| $65M-96.2% | $1.71B-8.9% | $1.87B+558% | $285M+265% | $78M+66.0% | ||
| -$131M+91.0% | -$1.46B+14.3% | -$1.7B-260% | -$473M+5.2% | -$499M-155% | ||
| $1.28B+1.7% | $1.26B-0.1% | $1.26B+0.1% | $1.26B+0.3% | $1.26B+3.3% | ||
| $500M-95.0% | $10.07B+4,297% | $229M-64.4% | $643M— | $0— | ||
| -$1.56B+74.1% | -$6.03B-305% | -$1.49B+18.8% | -$1.84B-84.9% | -$993M— | ||
| -$48M-1,060% | $5M— | $0-100% | $128M+93.9% | $66M+145% | ||
| -$635M+88.5% | -$5.51B-277% | $3.12B+79.4% | $1.74B+229% | $528M— | ||
| $94M-93.3% | $1.39B+120% | $633M-58.0% | $1.51B+702% | $188M+527% | ||
| —— | $15M— | $0-100% | $336M— | $0— | ||
| $34M— | —— | —— | —— | $292M+4.4% | ||
| $412M-29.5% | $584M+198% | $196M-37.4% | $313M+6,160% | $5M-99.7% | ||
| -$3.5B-45.7% | -$2.4B-241% | $1.7B+93.3% | $881M+241% | -$627M— | ||
| -$21M+93.2% | -$308M-516% | $74M+957% | $7M+240% | -$5M— | ||
| $312M— | —— | —— | —— | $243M-11.6% | ||
| $359M-10.7% | $402M-51.5% | $829M+58.2% | $524M+138% | $220M+255% | ||
| $391M+2,344% | $16M-67.3% | $49M— | $0-100% | $12M-94.1% | ||
| -$98M-197% | -$33M-1,000% | -$3M— | $0+100% | -$103M-442% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $321M— | —— | $5M-91.4% | $58M-84.2% | $368M— | ||
| —— | $0— | $0— | —— | —— | ||
| $757M-52.8% | $1.6B-73.2% | $5.99B+68.5% | $3.56B+110% | $1.69B-58.3% | ||
| $757M-52.8% | $1.6B-73.2% | $5.99B+68.5% | $3.56B+110% | $1.69B-58.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Bristol-Myers Squibb generate?
- Bristol-Myers Squibb (BMY) generated $13.3B in operating cash flow over the trailing twelve months.
- What is Bristol-Myers Squibb's free cash flow?
- After $1.4B of capital expenditures, Bristol-Myers Squibb's free cash flow was $11.9B over the trailing twelve months, down 9.0% year over year.
- Where does Bristol-Myers Squibb's cash flow data come from?
- Every line is extracted from Bristol-Myers Squibb's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
